Show Notes
N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Zak Mir talks to Fulcrum Metals CEO on reprocessing strategy and TR1 activity
In this interview, Zak Mir speaks with Fulcrum Metals CEO Ryan Mee about the com -
Zak Mir in conversation with Howard White, Chairman of Hydrogen Utopia
Zak Mir caught up with Howard White, Chairman of Hydrogen Utopia, to discuss th -
Zak Mir talks Ajax Resources with CEO Ippolito Cattaneo
Zak Mir talks to Ippolito Cattaneo, CEO of Ajax Resources, in the wake of the h -
Zak Mir in conversation with Colin Bird on Kendrick’s Namibia rare earth deal
Zak Mir talks to Colin Bird, Executive Chairman, Kendrick Resources, as the min